Viracta Logo_Color[30].jpg
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 16:05 ET | Viracta Therapeutics, Inc.
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from...
Viracta Logo_Color[30].jpg
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
February 29, 2024 08:00 ET | Viracta Therapeutics, Inc.
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of...
Viracta Logo_Color[30].jpg
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 16:05 ET | Viracta Therapeutics, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Viracta Logo_Color[30].jpg
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
January 04, 2024 08:00 ET | Viracta Therapeutics, Inc.
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in...
Viracta Logo_Color[30].jpg
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
December 12, 2023 08:00 ET | Viracta Therapeutics, Inc.
First orphan drug designation for Nana-val granted in EBV+ solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE...
Viracta Logo_Color[30].jpg
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
December 04, 2023 08:30 ET | Viracta Therapeutics, Inc.
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily...
Viracta Logo_Color[30].jpg
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 08:30 ET | Viracta Therapeutics, Inc.
Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and...
Viracta Logo_Color[30].jpg
Viracta Therapeutics to Present at Upcoming Investor Conferences
November 07, 2023 16:15 ET | Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Viracta Logo_Color[30].jpg
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
October 04, 2023 07:00 ET | Viracta Therapeutics, Inc.
Preliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from...
Viracta Logo_Color[30].jpg
Viracta Therapeutics to Host R&D Day on October 4, 2023
September 05, 2023 09:00 ET | Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...